Phlexglobal names John McNeill as CEO

Rick Riegel, CEO moves to new role as Vice-Chairman of the Phlexglobal Board of Directors.

John McClain

The opportunity ahead for Phlexglobal is significant, and I look forward to accelerating the company’s growth trajectory and market leadership.”

-John McNeill, CEO Phlexglobal

 

News

Amersham, UK; Malvern, PA. January 14, 2019 — Phlexglobal today announced that its Board of Directors has appointed John McNeill as Chief Executive Officer and member of the Board of Directors effective January 14, 2019. McNeill previously held the position of President at Sparta Systems, Inc.

“John McNeill is ideally placed to lead Phlexglobal”, said Rick Riegel.  “John is a proven life sciences industry veteran with demonstrated leadership, customer focus, product understanding and results. His vision for success will greatly benefit Phlexglobal as the company enters its next stage of further innovation and growth.”  In addition to the appointment of John McNeill as CEO, Phlexglobal also announced that Rick Riegel has moved to the position of Vice-Chairman.

Prior to joining Phlexglobal, McNeill was a key member of the executive team at Sparta Systems for 7 years, helping to build out Sparta’s market leading and global solution for quality management systems for the life sciences and other regulated industries. During his tenure, Sparta increased market share and successfully transitioned to a cloud-based SaaS business model.  Prior to Sparta, John held leadership positions at IRI, BravoSolution, and VerticalNet. 

Digital Brain Header Large Brain Right

It's time to raise your standard 

CONTACT PHLEXGLOBAL TODAY
 
Contact Us

Latest News

Overcoming TMF misfiles and metadata errors to reduce inspection risk

Trial master file misfiles are a common occurrence, with as many as one in every 10 documents being misfiled.   In some ways, misfiles are an even greater issue now with eTMF systems, where filing is

TMF Management in Clinical Trials Blog 3: Running the Trial in Your eTMF

Introduction Well, first and foremost, welcome!   Rob Jones has relinquished control and I’ve been given free rein to bring you the last blog in the series on TMF Management in Clinical Trials. Those

TMF Management in Clinical Trials Blog 2: The Path to Metric Nirvana

Good morning, good afternoon, good evening (I like to cover every possibility because who knows when you are reading this)! I hope you all enjoyed part one of this series where we talked about the